IBYME   02675
INSTITUTO DE BIOLOGIA Y MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Capitalizing on Galectin-1-glycan interactions for the design of novel therapeutic strategies in inflammatory bowel diseases (IBD)
Autor/es:
MARIÑO, KARINA VALERIA; RABINOVICH, GABRIEL A.
Lugar:
San Francisco
Reunión:
Congreso; 2016 Innovations Symposium: Emerging IBD strategies; 2016
Institución organizadora:
Kenneth Rainin Foundation
Resumen:
Galectin-1 (Gal1), a carbohydrate-binding protein, can exert protective and immunomodulatory activity in models of inflammatory diseases. The mechanisms underlying the anti-inflammatory effects of Gal1 are complex and include control of effector T cell survival, cytokine balance, and generation of tolerogenic dendritic cells. However, the therapeutic role of this lectin in intestinal inflammation has been only assessed in an acute TNBS-model of colitis. Given that no experimental model of colitis fully resembles human disease, in this project we aim to: a) understand the role of Gal1 and its carbohydrate ligands on the development and resolution of intestinal inflammation and test its therapeutic potential in DSS-induced colitis (more representative of ulcerative colitis) and T-cell transfer models; b) study the role of the Gal1-glycan axis in dysregulation of immune responses during intestinal inflammation; c) assess the therapeutic effects of Gal1 variants specifically designed to overcome adverse inflammatory microenvironments during intestinal inflammation.